A Single-Blind, Randomized, Controlled Trial Comparing BNT162b2 vs JNJ-78436735 Vaccine as a Booster Dose After Completion of BNT162b2 Vaccine in Solid Organ Transplant Recipients
Latest Information Update: 06 Feb 2024
At a glance
- Drugs Ad26.COV2 S (Primary) ; Tozinameran (Primary)
- Indications COVID 2019 infections; SARS-CoV-2 acute respiratory disease
- Focus Pharmacodynamics
- 20 Jun 2023 Status changed from completed to discontinued.
- 25 Oct 2022 Status changed from active, no longer recruiting to completed.
- 01 Aug 2022 Planned End Date changed from 30 Jul 2022 to 30 Oct 2022.